Welcome to our dedicated page for Tiziana Life Sciences Com SEC filings (Ticker: TLSA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tiziana Life Sciences Ltd. (NASDAQ: TLSA) SEC filings page provides access to the company’s official regulatory disclosures as a foreign private issuer. Tiziana files its annual report on Form 20-F and furnishes current reports on Form 6-K under the Securities Exchange Act of 1934. These filings include press releases and formal updates on clinical, regulatory, and corporate developments.
For investors analyzing Tiziana’s clinical-stage biopharmaceutical business, Form 6-K reports are particularly important. Recent 6-Ks have furnished announcements about the dosing of the first patient in a Phase 2 randomized, placebo-controlled trial of intranasal foralumab in early Alzheimer’s disease, the initiation of enrolment for that trial, and the inclusion of the company’s ALS Phase 2 study in the ALS MyMatch Program. Other 6-K filings describe insider share purchases by the Chief Executive Officer, the withdrawal of a proposed public offering of common shares due to market conditions, interim financial results and corporate updates on lead programs, and participation in global healthcare conferences.
Tiziana also reports on safety and regulatory interactions for intranasal foralumab, including Development Safety Update Reports submitted to the U.S. Food and Drug Administration that summarize cumulative exposure and serious adverse event findings across neuroinflammatory indications. While these safety reports themselves are submitted to regulators, related information may be discussed in filed or furnished documents.
On this page, users can review Tiziana’s 20-F annual report for a comprehensive overview of its business and risk factors, and track ongoing 6-K filings for timely information on clinical milestones, strategic plans such as the intended spinout of IL-6 asset TZLS-501, and capital markets activities. Stock Titan enhances these filings with AI-powered summaries that explain key points from lengthy documents, highlight material disclosures, and make it easier to understand how each filing may relate to Tiziana’s intranasal immunotherapy programs and overall corporate strategy.
Tiziana Life Sciences LTD filed a report stating that it will present a scientific poster at the 41st Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS), held September 24–26, 2025 in Barcelona, Spain. ECTRIMS is described as the world’s largest annual international conference focused on basic and clinical research in multiple sclerosis, bringing together leading scientists, clinicians, and industry partners.
The company’s press release with further details is furnished as Exhibit 99.1 to this report and is not incorporated by reference into other securities filings unless specifically referenced.
Tiziana Life Sciences LTD reported that the U.S. Department of Defense has awarded a research grant to study its intranasal anti-CD3 therapy in traumatic spinal cord injury. This program aims to evaluate whether the company’s intranasal anti-CD3 platform, previously focused on autoimmune and neuroinflammatory diseases, can be applied to severe neurological trauma such as spinal cord injury. The grant supports Tiziana’s strategy to expand this platform into larger, underserved neurological indications, potentially broadening the future scope of its therapeutic pipeline.
Tiziana Life Sciences LTD filed a Form 6-K to report that Chief Executive Officer Ivor Elrifi purchased 14,848 shares of Tiziana common stock in the open market at $1.65 per share on September 9, 2025. This transaction increases his total purchased shareholding to 193,848 shares.
The filing also notes that this purchase updates and corrects an earlier press release issued the same day, and includes the related press release as an exhibit.
Tiziana Life Sciences LTD reported that its Chief Executive Officer, Ivor Elrifi, purchased 193,848 shares of Tiziana common stock in the open market. The shares were bought at a price of $1.65 per share, indicating a direct increase in the CEO’s personal ownership stake. This transaction was disclosed in a Form 6-K, with additional details provided in a press release attached as an exhibit.
On September 5, 2025, Tiziana Life Sciences LTD reported that its Executive Chairman and Founder, Gabriele Cerrone, purchased 25,000 common shares at $1.60 per share. This transaction increased his total holding to 43,277,143 common shares, representing 36.28% of the company’s issued share capital. The move signals a larger personal stake by the company’s top insider, aligning his interests more closely with other shareholders.
Tiziana Life Sciences reported that the first participant has been enrolled and dosed in its Phase 2a clinical trial evaluating intranasal foralumab in patients with Multiple System Atrophy (MSA) at Brigham and Women's Hospital in Boston. The Form 6-K furnishes a press release as Exhibit 99.1 and states the exhibit is being furnished, not filed, under applicable securities rules. The disclosure provides the enrollment and site details only and does not include trial results, enrollment targets, dosing schedules, safety data, or timelines.
Tiziana Life Sciences reported that the U.S. Food and Drug Administration has approved an Investigational New Drug (IND) application for a Phase 2a clinical trial of intranasal foralumab in patients with Multiple System Atrophy (MSA).
The company states MSA is an unmet medical need with no FDA-approved therapies and is described as an orphan-designated disease. The announcement is furnished as Exhibit 99.1 to this Form 6-K.